<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">rpmj</journal-id><journal-title-group><journal-title xml:lang="ru">Research'n Practical Medicine Journal</journal-title><trans-title-group xml:lang="en"><trans-title>Research and Practical Medicine Journal</trans-title></trans-title-group></journal-title-group><issn pub-type="epub">2410-1893</issn><publisher><publisher-name>"QUASAR", LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.17709/2409-2231-2019-6-3-1</article-id><article-id custom-type="elpub" pub-id-type="custom">rpmj-417</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>Оригинальные статьи. Онкология, лучевая терапия</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>Original Articles. Оncology</subject></subj-group></article-categories><title-group><article-title>АССОЦИАЦИЯ ЭКСПРЕССИИ ГЕНОВ NFKB1, HIF1, VEGFA, VEGFВ, BAX, BCL2 С БИОХИМИЧЕСКИМ РЕЦИДИВИРОВАНИЕМ У БОЛЬНЫХ ЛОКАЛИЗОВАННЫМ РАКОМ ПРЕДСТАТЕЛЬНОЙ ЖЕЛЕЗЫ</article-title><trans-title-group xml:lang="en"><trans-title>ASSOCIATION OF EXPRESSION OF NFKB1, HIF1, VEGFA, VEGFВ, BAX, BCL2 GENES WITH BIOCHEMICAL REMEDIATION IN PATIENTS WITH LOCALIZED PROSTATE CANCER</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-2782-3288</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Бова</surname><given-names>Ф. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Bova</surname><given-names>Ph. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>к.м.н., докторант</p></bio><bio xml:lang="en"><p>MD, PhD, doctoral candidate</p></bio><email xlink:type="simple">alald@inbox.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-3061-6108</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Кит</surname><given-names>О. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Kit</surname><given-names>O. I.</given-names></name></name-alternatives><bio xml:lang="ru"><p>член-корреспондент РАН, д.м.н., профессор, генеральный директор</p></bio><bio xml:lang="en"><p>Member Russian Academy of Sciences, MD, PhD, DSc, professor, general director</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-1397-837X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Максимов</surname><given-names>А. Ю.</given-names></name><name name-style="western" xml:lang="en"><surname>Maksimov</surname><given-names>A. Yu.</given-names></name></name-alternatives><bio xml:lang="ru"><p>д.м.н., профессор, заместитель директора</p></bio><bio xml:lang="en"><p>MD, PhD, DSc, professor, deputy director</p></bio><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБУ «Ростовский научно-исследовательский онкологический институт» Министерства здравоохранения Российской Федерации</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Rostov Research Institute of Oncology (RRIO)</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2019</year></pub-date><pub-date pub-type="epub"><day>04</day><month>09</month><year>2019</year></pub-date><volume>6</volume><issue>3</issue><fpage>10</fpage><lpage>19</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Бова Ф.С., Кит О.И., Максимов А.Ю., 2019</copyright-statement><copyright-year>2019</copyright-year><copyright-holder xml:lang="ru">Бова Ф.С., Кит О.И., Максимов А.Ю.</copyright-holder><copyright-holder xml:lang="en">Bova P.S., Kit O.I., Maksimov A.Y.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.rpmj.ru/rpmj/article/view/417">https://www.rpmj.ru/rpmj/article/view/417</self-uri><abstract><sec><title>Цель исследования</title><p>Цель исследования. Идентифицировать ассоциацию экспрессии генов NFKB1, HIF1, VEGFA, VEGFВ, BAX, BCL2 в клетках аденокарциномы предстательной железы с биохимическим рецидивированием локализованного рака простаты.</p></sec><sec><title>Пациенты и методы</title><p>Пациенты и методы. В исследовании формировали три группы больных — основную, группу сравнения и контрольную группу. У больных раком предстательной железы (РПЖ) в основной группе (n = 56) при наличии биохимического рецидива (БР) в течение 2 лет после радикальной операции, а также у 60 пациентов без БР (группа сравнения) методом полимеразной цепной реакции (ПЦР) в реальном времени в ткани рака простаты определяли экспрессию генов NFKB1, HIF1, VEGFA, VEGFВ, BAX, BCL2. Контрольную группу составили 55 пациентов, у которых при выполнении диагностический биопсии при подозрении на РПЖ были взяты биоптаты в пределах здоровых тканей. Возраст пациентов трех групп варьировал от 57 до 74 лет (медиана 63 года). При количественной оценке экспрессии генов NFKB1, HIF1, VEGFA, VEGFВ, BAX, BCL2 определяли разность значений пороговых циклов реакции (Ct), установленных для изучаемого и референсного генов. Относительный уровень (Expr) представлял собой отношение медиан Ct для каждого гена в двух сравниваемых группах из трех изучаемых: в основной группе — к показателю в контрольной группе, в группе сравнения — показателю в контроле, а также между основной группой и группой сравнения.</p></sec><sec><title>Результаты</title><p>Результаты. При сравнительном анализе экспрессии генов в ткани рака простаты основной группы и группы сравнения установлено статистически значимое повышение (p &lt; 0,05) относительного показателя для гена HIF1 (в 2,7 раза), гена VEGFA (в 2,4 раза) и гена NFKB1 (в 2 раза). Следовательно, у пациентов с локализованным РПЖ при раннем рецидивировании исходно в ткани предстательной железы установлен более высокий уровень экспрессии генов NFKB1, HIF1 и VEGFA. В группе сравнения по отношению к контрольной группе экспрессия проапоптического гена BAX была выше в 1,6 раза (p &lt; 0,05), а для антиапоптического гена ВCL2 изменений не выявлено (р = 0,09). Таким образом, у пациентов с локализованным РПЖ при отсутствии БР после радикальной простатэктомии исходно повышение экспрессии гена BAX способствовало активации процессов апоптоза. У пациентов с локализованным РПЖ при последующем биохимическом рецидивировании изначально в ткани аденокарциномы простаты наблюдалось угнетение апоптоза за счет повышения экспрессии гена BCL2.</p></sec><sec><title>Заключение</title><p>Заключение. Усиление экспрессии генов NFKB1, VEGFA, HIF1 и BCL2 в ткани предстательной железы ассоциировано с развитием БР у больных локализованным РПЖ.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Aim</title><p>Aim. To identify the association of NFKB1, HIF1, VEGFA, VEGFB, BAX, BCL2 gene expression in prostate adenocarcinoma cells with biochemical recurrence of localized prostate cancer.</p></sec><sec><title>Patients and methods</title><p>Patients and methods. Three groups of patients were formed in the study – the main one, the comparison group and the control group. In patients with prostate cancer (PC) in the main group (n = 56) with biochemical recurrence (BR) for two years after radical surgery, as well as in 60 patients without BR (experimental group) by real-time PCR in prostate cancer tissue the expression of genes NFKB1, HIF1, VEGFA, VEGFВ, BAX, BCL2 was determined. The control group consisted of 55 patients in whom, when performing diagnostic punctures for benign prostate tumors, biopsy specimens were taken in healthy tissues. The age of patients in the three groups ranged from 57 to 74 years (median 63 years). When quantifying expression of genes NFKB1, HIF1, VEGFA, VEGFВ, BAX, BCL2, the difference in the values of reaction threshold cycles (Ct) fixed for the studied and reference genes was determined. The relative level (Expr) was the ratio of Ct medians for each gene in two compared groups of the studied three ones: in the main group to the indicator in the control group, in the experimental group to the indicator in the control group, and also between the main group and the experimental group.</p></sec><sec><title>Results</title><p>Results. A comparative analysis of gene expression in prostate cancer tissue in the main group compared with the experimental group showed a statistically significant increase (p &lt; 0,05) in the relative index for the HIF1 gene (2,7 times), the VEGFA gene (2,4 times ) and the NFKB1 gene (2 times). Consequently, in patients with localized early recurrence prostate cancer, initially in the prostate tissue, a higher level of expression of the NFKB1, HIF1 and VEGFA genes was established. In the experimental group relative to the control group, the expression of the proapoptic gene BAX was 1,6 times higher (p &lt; 0,05), and for the antiapoptic gene BCL2 no changes were detected (p = 0,09). Thus, in patients with localized prostate cancer in the absence of BR, after radical prostatectomy, an initial increase in the expression of the BAX gene promoted the activation of apoptosis. In patients with localized prostate cancer, subsequent biochemical recurrence initially in the tissue of prostate adenocarcinoma inhibition of apoptosis due to increased expression of the BCL2 gene was observed.</p></sec><sec><title>Conclusion</title><p>Conclusion. Enhancement of NFKB1, VEGFA, HIF1 and BCL2 gene expression in prostate tissue is associated with the development of BR in patients with localized prostate cancer.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>рак предстательной железы</kwd><kwd>биохимический рецидив</kwd><kwd>экспрессия генов</kwd><kwd>транскрипция</kwd><kwd>неоангиогенез</kwd><kwd>прогностические маркеры</kwd></kwd-group><kwd-group xml:lang="en"><kwd>prostate cancer</kwd><kwd>biochemical recurrence</kwd><kwd>gene expression</kwd><kwd>transcription</kwd><kwd>neoangiogenesis</kwd><kwd>prognostic markers</kwd></kwd-group><funding-group><funding-statement xml:lang="ru">Финансирование данной работы не проводилось.</funding-statement><funding-statement xml:lang="en">No funding of this work has been held.</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Iommarini L, Ghelli A, Gasparre G, Porcelli AM. Mitochondrial metabolism and energy sensing in tumor progression. Biochim Biophys Acta Bioenerg. 2017 Aug;1858 (8):582–590. DOI: 10.1016/j.bbabio.2017.02.006</mixed-citation><mixed-citation xml:lang="en">Iommarini L, Ghelli A, Gasparre G, Porcelli AM. Mitochondrial metabolism and energy sensing in tumor progression. Biochim Biophys Acta Bioenerg. 2017 Aug;1858 (8):582–590. DOI: 10.1016/j.bbabio.2017.02.006</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Гулиев Ф. А. Предикторы биохимического прогрессирования рака предстательной железы. Казанский медицинский журнал. 2017;98 (6):890–4. DOI: 10.17750/KMJ2017–890</mixed-citation><mixed-citation xml:lang="en">Guliev FA. Predictors of biochemical recurrence of prostate cancer. Kazan Medical Journal. 2017;98 (6):890–4. DOI: 10.17750/ KMJ2017–890 (In Russian).</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Al Olama AA, Kote-Jarai Z, Giles GG, Guy M, Morrison J, Severi G, et al. Multiple loci on 8q24 associated with prostate cancer susceptibility. Nat Genet. 2009 Oct;41 (10):1058–60. DOI: 10.1038/ng.452</mixed-citation><mixed-citation xml:lang="en">Al Olama AA, Kote-Jarai Z, Giles GG, Guy M, Morrison J, Severi G, et al. Multiple loci on 8q24 associated with prostate cancer susceptibility. Nat Genet. 2009 Oct;41 (10):1058–60. DOI: 10.1038/ng.452</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Iafrate AJ, Feuk L, Rivera MN, Listewnik ML, Donahoe PK, Qi Y, et al. Detection of large scale variation in the human genome. Nat Genet. 2004 Sep;36 (9):949–51. DOI: 10.1038/ng1416</mixed-citation><mixed-citation xml:lang="en">Iafrate AJ, Feuk L, Rivera MN, Listewnik ML, Donahoe PK, Qi Y, et al. Detection of large scale variation in the human genome. Nat Genet. 2004 Sep;36 (9):949–51. DOI: 10.1038/ng1416</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Kader T, Goode DL, Wong SQ, Connaughton J, Rowley SM, Devereux L, et al. Copy number analysis by low coverage whole genome sequencing using ultra low-input DNA from formalin-ﬁxed paraﬃn embedded tumor tissue. Genome Med. 2016 Nov 15;8 (1):121. DOI: 10.1186/s13073–016–0375-z</mixed-citation><mixed-citation xml:lang="en">Kader T, Goode DL, Wong SQ, Connaughton J, Rowley SM, Devereux L, et al. Copy number analysis by low coverage whole genome sequencing using ultra low-input DNA from formalin-ﬁxed paraﬃn embedded tumor tissue. Genome Med. 2016 Nov 15;8 (1):121. DOI: 10.1186/s13073–016–0375-z</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Junnila S, Kokkola A, Karjalainen-Lindsberg M, Puolakkainen P, Monni O. Genome-wide gene copy number and expression analysis of primary gastric tumors and gastric cancer cell lines. BMC Cancer. 2010 Mar 1;10:73. DOI: 10.1186/1471–2407–10–73</mixed-citation><mixed-citation xml:lang="en">Junnila S, Kokkola A, Karjalainen-Lindsberg M, Puolakkainen P, Monni O. Genome-wide gene copy number and expression analysis of primary gastric tumors and gastric cancer cell lines. BMC Cancer. 2010 Mar 1;10:73. DOI: 10.1186/1471–2407–10–73</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Lupski JR. Genomic rearrangements and sporadic disease. Nat Genet. 2007 Jul;39 (7 Suppl): S43–7. DOI: 10.1038/ng2084</mixed-citation><mixed-citation xml:lang="en">Lupski JR. Genomic rearrangements and sporadic disease. Nat Genet. 2007 Jul;39 (7 Suppl): S43–7. DOI: 10.1038/ng2084</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Zarrei M, MacDonald JR, Merico D, Scherer SW. A copy number variation map of the human genome. Nat Rev Genet. 2015 Mar;16 (3):172–83. DOI: 10.1038/nrg3871.</mixed-citation><mixed-citation xml:lang="en">Zarrei M, MacDonald JR, Merico D, Scherer SW. A copy number variation map of the human genome. Nat Rev Genet. 2015 Mar;16 (3):172–83. DOI: 10.1038/nrg3871.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Majmundar AJ, Wong WJ, Simon MC. Hypoxia-inducible factors and the response to hypoxic stress. Mol Cell. 2010 Oct 22;40 (2):294–309. DOI: 10.1016/j.molcel.2010.09.022</mixed-citation><mixed-citation xml:lang="en">Majmundar AJ, Wong WJ, Simon MC. Hypoxia-inducible factors and the response to hypoxic stress. Mol Cell. 2010 Oct 22;40 (2):294–309. DOI: 10.1016/j.molcel.2010.09.022</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Maruyama W, Shirakawa K, Matsui H. Classical NF-kappa B pathway is responsible for APOBEC3 B expression in cancer cells. Biochem Biophys Res Commun. 2016 Sep 23;478 (3):1466–71. DOI: 10.1016/j.bbrc.2016.08.148.</mixed-citation><mixed-citation xml:lang="en">Maruyama W, Shirakawa K, Matsui H. Classical NF-kappa B pathway is responsible for APOBEC3 B expression in cancer cells. Biochem Biophys Res Commun. 2016 Sep 23;478 (3):1466–71. DOI: 10.1016/j.bbrc.2016.08.148.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Liu ZQ, Fang JM, Xiao YY, Zhao Y, Cui R, Hu F, Xu Q. Prognostic role of vascular endothelial growth factor in prostate cancer: A systematic review and meta-analysis. Int J Clin Exp Med. 2015 Feb 15;8 (2):2289–98.</mixed-citation><mixed-citation xml:lang="en">Liu ZQ, Fang JM, Xiao YY, Zhao Y, Cui R, Hu F, Xu Q. Prognostic role of vascular endothelial growth factor in prostate cancer: A systematic review and meta-analysis. Int J Clin Exp Med. 2015 Feb 15;8 (2):2289–98.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Rivera-Perez J, Monter-Vera M, Barrientos-Alvarado C, Toscano-Garibay JD, Cuesta-Mejías T, Flores-Estrada J. Evaluation of VEGF and PEDF in prostate cancer: A preliminary study in serum and biopsies. Oncol Lett. 2018 Jan;15 (1):1072–1078. DOI: 10.3892/ol.2017.7374</mixed-citation><mixed-citation xml:lang="en">Rivera-Perez J, Monter-Vera M, Barrientos-Alvarado C, Toscano-Garibay JD, Cuesta-Mejías T, Flores-Estrada J. Evaluation of VEGF and PEDF in prostate cancer: A preliminary study in serum and biopsies. Oncol Lett. 2018 Jan;15 (1):1072–1078. DOI: 10.3892/ol.2017.7374</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Huss WJ, Hanrahan CF, Barrios RJ, Simons JW, Greenberg NM. Angiogenesis and Prostate Cancer: Identiﬁcation of A Molecular Progression Switch. Cancer Res. 2001 Mar 15;61 (6):2736–43.</mixed-citation><mixed-citation xml:lang="en">Huss WJ, Hanrahan CF, Barrios RJ, Simons JW, Greenberg NM. Angiogenesis and Prostate Cancer: Identiﬁcation of A Molecular Progression Switch. Cancer Res. 2001 Mar 15;61 (6):2736–43.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Prior S, Kim A, Yoshihara T, Tobita S, Takeuchi T, Higuchi M. Mitochondrial respiratory function induces endogenous hypoxia. PLoS One. 2014 Feb 21;9 (2): e88911. DOI: 10.1371/journal.pone.0088911</mixed-citation><mixed-citation xml:lang="en">Prior S, Kim A, Yoshihara T, Tobita S, Takeuchi T, Higuchi M. Mitochondrial respiratory function induces endogenous hypoxia. PLoS One. 2014 Feb 21;9 (2): e88911. DOI: 10.1371/ journal.pone.0088911</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Anvari K, Toussi MS, Kalantari M, Naseri S. Expression of Bcl-2 and Bax in advanced or metastatic prostate carcinoma. Urol J. 2012 Winter;9 (1):381–8.</mixed-citation><mixed-citation xml:lang="en">Anvari K, Toussi MS, Kalantari M, Naseri S. Expression of Bcl-2 and Bax in advanced or metastatic prostate carcinoma. Urol J. 2012 Winter;9 (1):381–8.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Renner W, Langsenlehner U, Krenn-Pilko S, Eder P, Langsenlehner T. BCL2 genotypes and prostate cancer survival. Strahlenther Onkol. 2017 Jun;193 (6):466–471. DOI: 10.1007/s00066–017–1126–9</mixed-citation><mixed-citation xml:lang="en">Renner W, Langsenlehner U, Krenn-Pilko S, Eder P, Langsenlehner T. BCL2 genotypes and prostate cancer survival. Strahlenther Onkol. 2017 Jun;193 (6):466–471. DOI: 10.1007/s00066–017– 1126–9</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Черняев В. А. VEGF и рак предстательной железы. РМЖ. Онкология. 2012;1:17–19.</mixed-citation><mixed-citation xml:lang="en">Chernjaev VA. VEGF and prostate cancer. RMJ (Russian Medical Journal). 2012;1:17–19. (In Russian).</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Eisermann K, Fraizer G. The androgen receptor and VEGF: mechanisms of androgen-regulated angiogenesis in prostate cancer. Cancers (Basel). 2017 Apr 10;9 (4). pii: E32. DOI: 10.3390/cancers9040032.</mixed-citation><mixed-citation xml:lang="en">Eisermann K, Fraizer G. The androgen receptor and VEGF: mechanisms of androgen-regulated angiogenesis in prostate cancer. Cancers (Basel). 2017 Apr 10;9 (4). pii: E32. DOI: 10.3390/ cancers9040032.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Ma T, Yang S, Jing H, Cong L, Cao Z, Liu Z, Huang Z. Apparent diﬀusion coeﬃcients in prostate cancer: correlation with molecular markers Ki-67, HIF-1α and VEGF. NMR Biomed. 2018 Mar;31 (3). DOI: 10.1002/nbm.3884.</mixed-citation><mixed-citation xml:lang="en">Ma T, Yang S, Jing H, Cong L, Cao Z, Liu Z, Huang Z. Apparent diﬀusion coeﬃcients in prostate cancer: correlation with molecular markers Ki-67, HIF-1α and VEGF. NMR Biomed. 2018 Mar;31 (3).DOI: 10.1002/nbm.3884.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Ranasinghe WK, Sengupta S, Williams S, Chang M, Shulkes A, Bolton DM, et al. The eﬀects of nonspeciﬁc HIF1α inhibitors on development of castrate resistance and metastases in prostate cancer. Cancer Med. 2014 Apr;3 (2):245–51. DOI: 10.1002/cam4.189</mixed-citation><mixed-citation xml:lang="en">Ranasinghe WK, Sengupta S, Williams S, Chang M, Shulkes A, Bolton DM, et al. The eﬀects of nonspeciﬁc HIF1α inhibitors on development of castrate resistance and metastases in prostate cancer. Cancer Med. 2014 Apr;3 (2):245–51. DOI: 10.1002/cam4.189</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
